miércoles, 17 de mayo de 2017

Don't miss out on our latest Highly Accessed Articles | Journal for ImmunoTherapy of Cancer

BioMed Central – The Open Access Publisher

Dear Prof CERASALE MORTEO,

We would like to recommend a selection of our highly accessed articles from Journal for ImmunoTherapy of Cancer.

Journal for ImmunoTherapy of Cancer (JITC) is an open access, peer reviewed journal that encompasses all aspects of tumor immunology and cancer immunotherapy, from basic research through to clinical applications.

We hope that you find the articles below of interest and invite you to submit your next manuscript to the journal.


New SITC Guidelines
The Society for Immunotherapy of Cancer (SITC) has recently published guidelines for the use of immunotherapy to treat patients with prostate carcinoma, hematologic malignances, and renal cell carcinoma, as part of the Cancer Immunotherapy Guidelines series.

These guidelines are the first of their kind and represent the result of a multidisciplinary collaboration between academic researchers and physicians, nurses, patients, and patients advocates from throughout the U.S.

Reasons to Publish with Us
The official journal of the Society for ImmunoTherapy of Cancer (SITC)
Free article processing charges for SITC members
Distributed to over 15,000 individuals in the cancer treatment space and downloaded more than 800,000 times in 2015


Register to receive the latest articles, straight to your inbox.

Best regards,

The BioMed Central Team

PS. Visit our website to find out more about open access funding options that may be available to you.

SOCIETY AFFILIATION
OFFICIAL JOURNAL OF THE SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC)

For further information or enquiries please contact Customer Services at:info@biomedcentral.com.
BioMed Central Ltd 
236 Gray's Inn Road, London, WC1X 8HB, 



United Kingdom.

No hay comentarios:

Publicar un comentario